During a live event, Christine Bestvina, MD, discussed trials of KRAS inhibitors plus immunotherapy in patients with ...

These data support the use of sacituzumab plus pembrolizumab as a potential new standard of care,” said Sara Tolaney, MD.

A novel triple therapy shows promise for advanced triple-negative breast cancer, offering hope for patients with limited ...

IO Biotech’s off-the-shelf cancer vaccine shows promise in melanoma with key data ahead, but funding risk limits near-term ...

Vir Biotech begins patient dosing in phase 1 trial of EGFR-targeting PRO-XTEN dual-masked T-cell engager VIR-5525 to treat solid tumours: San Francisco Saturday, July 26, 2025, 12 ...

EXCLUSIVE: New mum Zara was shattered when told she had bowel cancer, but a new drug trial at The Christie in Manchester has ...

Revised Phase 2 Strategy Targets Event-Free Survival in Primary Head and Neck Cancer through Checkpoint Inhibitor Combination ...

That being said, we’re here with a list of the 10 most profitable new stocks to buy now. We sifted through the Finviz stock screener to compile a list of the top companies that went public in the last ...

Gilead Sciences ( ($GILD) ) has risen by 7.31%. Read on to learn why. Gilead Sciences has seen a notable increase in its ...

It will be piloted in Cambridge on the PemOla trial, a precision medicine study exploring a combination immunotherapy, using ...

The move has triggered a $75m milestone payment to Vir as part of its 2024 exclusive global licence agreement with Sanofi.

By sparking the immune system into action, radiation therapy makes certain tumors that resist immunotherapy susceptible to ...